Mirae Asset Global ETFs Holdings’s Astria Therapeutics ATXS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,187	Closed	-$251K	–	3125
2025 Q4	$251K	Buy	19,187 +2,134	+13%	+$25.5K	﹤0.01%	2242
2025 Q3	$124K	Sell	17,053 -6,340	-27%	-$42.9K	﹤0.01%	2571
2025 Q2	$125K	Sell	23,393 -4,513	-16%	-$21.9K	﹤0.01%	2493
2025 Q1	$149K	Buy	27,906 +633	+2%	+$4.43K	﹤0.01%	2461
2024 Q4	$244K	Buy	27,273 +525	+2%	+$5.58K	﹤0.01%	2285
2024 Q3	$295K	Sell	26,748 -3,419	-11%	-$38K	﹤0.01%	2175
2024 Q2	$275K	Buy	+30,167	New	+$295K	﹤0.01%	2107

Mirae Asset Global ETFs Holdings's ATXS Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 19,187 shares — an estimated $251K sold.

Mirae Asset Global ETFs Holdings first reported a position in ATXS in Q2 2024 and held it in 7 quarters. The position peaked at $295K in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Mirae Asset Global ETFs Holdings reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Mirae Asset Global ETFs Holdings sold 19,187 Astria Therapeutics shares in Q1 2026, an estimated $251K.
Mirae Asset Global ETFs Holdings first reported a position in Astria Therapeutics in Q2 2024 and held it in 7 quarters.
Mirae Asset Global ETFs Holdings's Astria Therapeutics position peaked at $295K in Q3 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.